When her stroke hit, Edna Wooten somehow stopped her car. Then her grown daughter ignored her slurred protests and raced her to the hospital - in time for a drug to dissolve the blood clot causing her stroke.
Geron Corp. has begun testing an embryonic stem-cell treatment on a patient with spinal cord injuries, marking the first time such a drug has been used on a human.
Parents who say their daughter allegedly suffered serious health problems from a childhood vaccine are trying to persuade the Supreme Court to allow them to sue the manufacturer.
Pfizer Inc., the world's largest pharmaceutical company by revenue, said it will buy pain drug maker King Pharmaceuticals Inc. for $3.6 billion in cash.
Keyence Corp.’s VHX-1000 digital microscope successfully integrates many of the optical properties and functionalities of stereoscopes, measuring microscopes, and scanning electron microscopes into an all-in-one.
JEOL USA, Inc. and the Japanese AIST have developed the ClairScope, a tool that couples optical microscopy with an atmospheric scanning electron microscope in an open culture system that retains the samples’ native state while under study.
VivaTome, an optical microscope accessory from Carl Zeiss and Aurox Ltd., addresses the problem of unwanted blurred information being included with the primary in-focus information from.
This month, I am pleased to share with you some features that are in our magazine, and some that are not. Editors are frequently frustrated by the physical limitations of the printed page.
In late September, the U.S. Food and Drug Administration issued a final rule that clarifies what safety information must be reported during clinical trials of investigational drugs and biologics.
Many articles describe assays that work in multi-well plates, but without the technology to read the results these assays are of limited benefit to the drug discovery and development process.
Harvard Apparatus offers the 192-Well DispoEquilibrium DIALYZERS that analyze up to 96 samples simultaneously on disposable dialysis plates.
Affymetrix has launched the GeneAtlas System to make Affymetrix microarrays accessible to all life science researchers.
ImmunoGen, Inc. announced that it has entered into a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis.
Exelixis, Inc. has entered into two collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.
A new lexicon that revises and unifies the definition of Alzheimer's disease to include recent developments in the field, in which biomarkers are the key to diagnosis, has been proposed by an international group of Alzheimer's disease experts.